Get the Stockscreener App
3.355
0.75%
0.025
Calcimedica Inc stock is traded at $3.355, with a volume of 32,191.
It is up +0.75% in the last 24 hours and down -17.77% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
See More
Previous Close:
$3.33
Open:
$3.33
24h Volume:
32,191
Relative Volume:
0.58
Market Cap:
$44.99M
Revenue:
-
Net Income/Loss:
$-34.36M
P/E Ratio:
-0.0939
EPS:
-35.74
Net Cash Flow:
$-25.81M
1W Performance:
-4.14%
1M Performance:
-17.77%
6M Performance:
-38.44%
1Y Performance:
-3.59%
1-Day Range:
$3.30
$3.43
1-Week Range:
$3.27
$3.56
52-Week Range:
$2.68
$8.38
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CALC | 3.39 | 44.99M | 0 | -34.36M | -25.81M | -35.74 |
| VRTX | 467.79 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 761.02 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.78 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.65 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Calcimedica Inc Stock (CALC) Latest News
CalciMedica’s (CALC) “Buy” Rating Reiterated at HC Wainwright - Defense World
Insiders Bet Big on These Small Cap Stocks - sharewise
CalciMedica reports Q3 EPS (50c), consensus (50c) - TipRanks
CalciMedica's Auxora Shows 100% Risk Reduction in Respiratory Failure, Extends Cash Runway | CALC Stock News - StockTitan
CalciMedica Appoints Stephen Bardin as New CFO - TipRanks
CalciMedica Appoints Chief Financial Officer - Contract Pharma
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer - Citizentribune
CalciMedica Names Ex-atai Life Sciences CFO to Lead Financial Strategy Amid Clinical Trials | CALC Stock News - StockTitan
CalciMedica director Fred Middleton acquires shares valued at $404,040 - Investing.com India
CalciMedica director Fred Middleton acquires shares valued at $404,040 By Investing.com - Investing.com Australia
CalciMedica sees significant stock purchase by Sanderling Ventures - Investing.com Canada
H.C. Wainwright cuts CalciMedica stock target to $16, keeps Buy rating - Investing.com Australia
Graybug Vision Suspends Stock Offering Amid Proposed Public Offering of CalciMedica - Defense World
Calcimedica director Robert Wilson acquires $199,998 in stock - Investing.com India
CalciMedica's chief business officer Eric Roberts acquires $199,998 in stock By Investing.com - Investing.com Australia
CalciMedica CEO Rachel Leheny acquires $75,000 in common stock By Investing.com - Investing.com Australia
Calcimedica director Robert Wilson acquires $199,998 in stock By Investing.com - Investing.com Australia
Director Robert Wilson Acquires 53,333 Shares of CalciMedica Inc (CALC) - GuruFocus.com
CalciMedica CEO Rachel Leheny acquires $75,000 in common stock - Investing.com
CalciMedica's chief business officer Eric Roberts acquires $199,998 in stock - Investing.com
CalciMedica announces proposed public offering of common stock - MSN
CalciMedica Announces Pricing of Public Offering of Common Stock - StockTitan
CalciMedica launches public stock offering - Investing.com
CalciMedica launches public stock offering By Investing.com - Investing.com UK
CalciMedica Announces Proposed Public Offering of Common Stock - StockTitan
CalciMedica, Inc. (NASDAQ:CALC) Sees Significant Decline in Short Interest - MarketBeat
CalciMedica’s Promising Phase 2b Trial Results for Auxora - TipRanks
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting - PR Newswire
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) - Citizentribune
Standard BioTools And 2 Other Penny Stocks Executives Are Buying - MSN
CalciMedica (NASDAQ:CALC) Stock Price Up 1% – Here’s What Happened - Defense World
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting - StockTitan
Scientech Research LLC Buys New Position in Grand Canyon Education, Inc. (NASDAQ:LOPE) - Defense World
Kenvue Inc. (NYSE:KVUE) Shares Bought by Brandes Investment Partners LP - Defense World
Regal Investment Advisors LLC Has $7.19 Million Holdings in AT&T Inc. (NYSE:T) - Defense World
LandBridge (NYSE:LB) and Texas Pacific Land (NYSE:TPL) Financial Comparison - Defense World
Baozun Inc. (NASDAQ:BZUN) Short Interest Update - Defense World
CalciMedica, Inc. (NASDAQ:CALC) Short Interest Up 5.1% in September - Defense World
Likewise Group (LON:LIKE) Stock Price Up 3.1% Following Dividend Announcement - Defense World
Senator Investment Group LP Acquires New Position in CleanSpark, Inc. (NASDAQ:CLSK) - Defense World
Evergreen Capital Management LLC Takes Position in IAC Inc. (NASDAQ:IAC) - Defense World
Caxton Associates LP Sells 4,741 Shares of Verizon Communications Inc. (NYSE:VZ) - Defense World
Regencell Bioscience (NASDAQ:RGC) Stock Quotes, Forecast and News Summary - Benzinga
Acute Pancreatitis Market Business Insights, Key Trend Analysis - Economica
CalciMedica (NASDAQ:CALC) Shares Down 2% - Defense World
CalciMedica (NASDAQ:CALC) Trading Down 2% - Defense World
Allegiant Travel (NASDAQ:ALGT) Issues Q3 2024 Earnings Guidance - MarketBeat
Milan stock market opens weak, luxury retraces, cues on doValue, down Lottomatica after Abb - Marketscreener.com
Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma - CGTLive™
Allete takeover will get a recommendation from Minnesota PUC's ALJ by July 15 - Seeking Alpha
CAH Stock Sees Decline of Approximately -1.71% in Last Five Days - Knox Daily
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):